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Abstract
Background: KRAS mutation testing is mandatory in the management of metastatic colorectal cancer prior to
treatment with anti-EGFR antibodies as patients whose tumors express mutant KRAS do not benefit from these
agents. Although the U.S. Food and Drug Administration has recently approved two in-vitro diagnostics kits for
determination of KRAS status, there is generally no consensus on the preferred method and new tests are
continuously being developed. Most of these techniques focus on the hotspot mutations at codons 12 and 13 of
the KRAS gene.
Methods: We describe a two-step approach to KRAS codon 12/13 mutation testing involving high resolution
melting analysis (HRM) followed by pyrosequencing using the Therascreen KRAS Pyro kit (Qiagen) of only those
samples that are not clearly identified as KRAS wildtype or mutant by HRM. First, we determined KRAS status in a
panel of 61 colorectal cancer samples using both methods to compare technical performance and concordance of
results. Subsequently, we evaluated practicability and costs of our concept in an independent set of 120 colorectal
cancer samples in a routine diagnostic setting.
Results: HRM and pyrosequencing appeared to be equally sensitive, allowing for clear detection of mutant alleles
at a mutant allele frequency ≥12.5 %. Pyrosequencing yielded more exploitable results due to lower input
requirements and a lower rate of analysis failures. KRAS codon 12/13 status was called concordantly for 98.2 % (56/
57) of all samples that could be successfully analysed by both methods and 100 % (19/19) of samples that were
identified mutant by HRM. Reviewing the actual effort and expenses for KRAS mutation testing in our laboratory
revealed, that the selective use of pyrosequencing for only those samples that could not be analysed by HRM
increased the fraction of valid results from 87.5 % for HRM alone to 99.2 % (119/120) while allowing for a net
reduction of operational costs of >75 % compared to pyrosequencing alone.
Conclusions: Combination of HRM and pyrosequencing in a two-step diagnostic procedure constitutes a reliable
and economic analysis platform for KRAS mutation testing in colorectal cancer in a clinical setting.
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Background
The anti EGFR-antibodies cetuximab and panitumumab
represent well-established treatments for metastatic
colorectal cancer (CRC), the third most prevalent cancer
entity and fourth most common cause of cancer-related
death around the world [1, 2]. Several studies have
shown KRAS status to predict outcome under these
anti-EGFR targeting agents, with beneficial effects being
seen only in patients whose tumors express wildtype
(WT) KRAS [3–8]. Thus, testing for KRAS mutations,
which are found in approximately 40 % of colorectal
cancers, has become routine in the management of
metastatic CRC (mCRC) prior to cetuximab or panitu-
mumab treatment [9, 10] and is even required by the re-
sponsible regulatory agencies. Notably, current standards
regarding oncogenic Ras mutation analysis in mCRC is-
sued by the U.S Food and Drug Administration (FDA)
require determination of KRAS status by an FDA-
approved test, while the European Medical Agency
(EMA) just states application of validated methods by an
experienced laboratory [11–15]. Currently available
FDA-approved companion diagnostic devices for cetuxi-
mab (Erbitux) and panitumumab (Vectibix) comprise
the Cobas KRAS Mutation Test (Roche) and Therascreen
KRAS RGQ PCR Kit (Qiagen) [16]. Besides these and
other commercially available kits, the spectrum of
methods for KRAS mutation testing encompasses mul-
tiple PCR-derived and sequencing-based techniques. Of
note, most of the previously established assays for KRAS
mutation detection focus on the hotspot mutations in-
volving codons 12 and 13, which account for >95 % of
Ras mutations in CRC [10]. The advantages and limita-
tions of selected methods have been repeatedly evaluated
comparatively [17–22], however, beyond the FDA-
guideline, there is no consensus on the preferred ap-
proach to investigate KRAS status in routine molecular
pathological diagnostics [23]. Given the high incidence
of CRC resulting in high demand for KRAS mutation
testing, an ideal diagnostic assay for this purpose not
only needs to be sufficiently sensitive and specific, but,
for socio-economic reasons, also should be time- and
cost-effective. Therefore, we developed a two-step
procedure for KRAS mutation testing including high
resolution melting analysis (HRM) followed by pyrose-
quencing of only those samples that are not clearly
identified as KRAS WT or mutant by HRM. HRM is a
one-tube qPCR-based technique for DNA-variant detec-
tion. The method utilizes alterations in the melting be-
havior of double-stranded DNA fragments that are
conferred by nucleotide exchanges. Melting of qPCR
amplicons is monitored in real time using a suitable
qPCR instrument capable of time-dense data aquisition
and a saturating DNA-intercalating fluorescent dye that
does not redistribute during the melting step [24].
Pyrosequencing is a sequencing-by-synthesis approach that
involves sequential addition of dNTPs and recording in-
corporation of a nucleotide based on a light signal that is
generated by sulfurylase-catalyzed conversion of the released
pyrophosphate to ATP and a subsequent luciferase reaction
[25]. Here, we applied a previously described HRM-assay
[20] and the Therascreen KRAS Pyro kit (Qiagen) for detec-
tion of KRAS codon 12/13 mutations. First we compara-
tively analysed KRAS status in a panel of 61 colon cancer
samples to determine sensitivity, specificity, technical per-
formance and concordance of results of the two methods.
Subsequently, we evaluated our two-step approach in the
routine setting of our molecular diagnostics laboratory. In
summary, we present a reliable, time- and cost-effective op-
erational concept for KRAS mutation testing prior to anti-
EGFR antibody treatment in mCRC.
Methods
Tumor samples, control cell lines and DNA isolation
The colorectal cancer samples reported on in this study
were obtained from patients with metastatic colorectal
cancer (UICC IV) at the University Hospital Marburg,
Germany and analysed in a routine diagnostic setting.
Tissue samples were fixed, paraffin-embedded, sec-
tioned, hematoxylin-eosin stained and deparaffinated
using standard procedures. Tissue sections were
reviewed by an experienced pathologist (RM) to establish
the diagnosis and to mark regions for microdissections.
Microdissection of tumor cells was performed from
deparaffinated sections using a scalpel. DNA was isolated
from microdissected samples using the QiaAmp DNA
Mini kit (Qiagen) as recommended by the manufacturer.
KRAS mutant cell lines PL45 (pancreatic adenocarcinoma)
and RPMI 8226 (multiple myeloma) were obtained from
ATCC and cultured according to standard cell culture
methods. Positive control DNA for HRM analyses was
isolated from these cell lines using the QiaAmp DNA
Mini kit. WT control DNA was extracted from peripheral
blood of healthy donors from whom informed consent
had been obtained (WT control) with the QiaAmp DNA
Mini kit. DNA concentrations were measured using a
Nanodrop 1000 spectrophotometer (Peqlab).
High resolution melting analysis
For HRM analysis, a 92 bp amplicon spanning exons 2
and 3 of the KRAS gene was amplified from 60 ng (or
less) of sample DNA using the primers KRAS-92_F 5′-
ttataaggcctgctgaaaatgactgaa-3′ and KRAS-92_R 5′-tgaat-
tagctgtatcgtcaaggcact-3′ [20], the DNA-intercalating dye
SYTO 9 (Thermo) in a final concentration of 5 μM and
Platinum Taq polymerase (Thermo). Amplification and
melting analysis was performed on a Rotor Gene 6000
instrument (Corbett Life Sciences) under the following
temperature conditions: one cycle 95 °C/2 min, 40 cycles
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95 °C/15 sec – 67.5 °C/15 sec - 72 °C/15 sec, one cycle
95 °C/1 sec, pre-melt conditioning at 72 °C/90 sec,
HRM-ramp from 72 °C to 95 °C rising at 0.2 °C per
step/wait 2 sec each step. Controls in each HRM run in-
cluded a no-template-control, a WT control (gDNA from
healthy donor) and two mutation controls (gDNA from
the cell lines RPMI 8226, KRAS codon 12 GGT→GCT/
heterozygous, corresponding to G12A and PL45, KRAS
codon 12 GGT→GAT/heterozygous, corresponding to
G12D). All HRM assays were performed in quadruplicate.
Pyrosequencing
Pyrosequencing of the KRAS codon 12/13 region was per-
formed using the Therascreen KRAS Pyro Kit (Qiagen) as
recommended by the manufacturer. 2 ng of DNA were
used per analysis. PCR amplification of the target region
was performed on a T-100 thermocycler (Biorad). For the
pyrosequencing reaction on the PyroMark Q24 platform
(Qiagen), amplicons were immobilized to the wells of a
PyroMark Q24 plate using streptavidin high performance
beads (GE Healthcare). Pyrosequencing results were ana-
lysed using the PyroMark Q24 software version 2.0 with
the Therascreen KRAS Pyro-plugin report, which already
incorporated the thresholds for mutation calls (detection
limit for the mutation (LOD) + 3 %).
Statistical analysis
HRM and pyrosequencing results were compared by con-
tingency table analysis test using GraphPad Prism 5 soft-
ware (GraphPad). Technical performance (1st run success
vs. 1st run failure) was evaluated by two-sided Fisher’s
exact test at a significance level of 5 %. The agreement be-
tween HRM and pyrosequencing results was quantified by
kappa using the appropriate Graphpad Prism online cal-
culator (http://graphpad.com/quickcalcs/kappa2).
Results
Sensitivity of HRM and pyrosequencing
In order to test whether pyrosequencing allows for
KRAS mutation detection with at least equal sensitivity
compared to HRM, we analysed serial dilutions of DNA
from a KRAS mutant cell line (PL45, codon 12 GGT→
GAT heterozygous mutation) in WT DNA by both
HRM and pyrosequencing. For HRM, we found, that the
presence of KRAS mutant DNA in the sample was
clearly reflected by a shifted or skewed melting curve for
Fig. 1 Sensitivity of HRM. Dilutions of genomic DNA from the KRAS mutant cell line PL45 (codon 12 GGT→GAT, heterozygous mutation) in WT
genomic DNA was analysed by HRM. Normalised fluorescence and difference graphs are indicated. Clear discrimination of WT and mutant amplicons
is possible using either graph if the fraction of PL45-DNA in the sample exceeds 25 %, corresponding to a mutant allele frequency of 12.5 %
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a fraction of PL45-DNA exceeding 25 %, which corre-
sponded to a mutant allele frequency of 12.5 % (Fig. 1).
Similarly, pyrosequencing definitely yielded a mutation if
the sample contained ≥25 % PL45-DNA. On the other
hand, samples with 5–10 % cell line DNA were indicated
to exhibit a potential low level mutation as the mutant
allele frequency was quantified below the threshold for
accurate WT/mutant discrimination for the G12D muta-
tion (LOD + 3 %; LOD = 2,2 %) for both the 5 and 10 %
samples (Fig. 2). Thus, HRM and pyrosequencing ap-
peared to be equally sensitive methods for the detection
of KRAS codon 12/13 mutations.
Fig. 2 Sensitivity of pyrosequencing. Dilutions of genomic DNA from the KRAS mutant cell line PL45 (codon 12 GGT→ GAT, heterozygous
mutation) in WT genomic DNA was analysed by pyrosequencing on the Pyromark Q24 platform. The WT sequence and the sequence to analyse
including wobble bases at the potentially mutant positions in the region of interest (codons 12 and 13) are indicated in the top panel. Lower
panels: KRAS codon 12/13 pyrograms for different dilutions of PL45-DNA in WT DNA. Clear mutation calls are obtained for samples containing
≥25 % of PL45-DNA, corresponding to 12.5 % mutant alleles. For lower concentrations, yielding signals below the LOD of the mutation (2.2 %) +
3 %, presence of a potential low level mutation is suggested, which requires technical and/or biological replication of the analysis
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Technical reliability of HRM and pyrosequencing
To further assess the suitability of pyrosequencing to
serve as a backup-assay allowing for accurate diagnosis
of KRAS mutation status in case of failed HRM analysis,
we investigated KRAS status of 61 colorectal cancer
samples by both HRM and pyrosequencing and com-
pared the two methods with regard to their technical
performance and concordance of results. In a first run of
HRM analysis, 11/61 samples (18.0 %) could not be ana-
lysed due to PCR-failures or ambiguous melting curves
(Table 1). Repetition of the assay for seven samples,
which most likely had been compromised technically,
allowed for assigning KRAS mutation status in all cases.
The remaining four samples were directly subjected to
pyrosequencing without a second round of HRM
analysis. Indeed, KRAS status could each be determined,
although one sample yielded a potential low level muta-
tion. Of the 57 samples that could be definitely classified
as KRAS WT or mutant by HRM, 26 WT samples
(45.6 % of all samples/68.4 % of WT samples) yielded
skewed HRM curves, which, however, did not prevent
establishment of a diagnosis (Tables 1 and 2). Moreover,
we noted that low DNA content of the samples below
Table 1 KRAS codon 12/13 status by HRM and pyrosequencing
in 61 CRC samples
HRM Pyrosequencing
Run 1 Run 2
Sample cDNA
[ng/μl]






1 11 failed WT a WT WT
2 31 WT a WT WT
3 10 WT a G12C 13.4 mut
4 93 WT a WT WT
5 26 WT a WT WT
6 27 WT a WT WT
7 10 WT a WT WT
8 43 mut G13D 73.9 mut
9 85 failed WT WT WT
10 N/A mut G13D 44.3 mut
11 N/A failed G12V 2.6 WT b
12 N/A WT WT WT
13 N/A mut G12V 41.9 mut
14 126 mut failed G12D 65.7 mut
15 133 mut G12D 74.1 mut
16 97 mut G13D 52.8 mut
17 47 failed WT WT WT
18 14 failed WT WT WT
19 44 WT a WT WT
20 20 failed WT a WT WT
21 N/A failed WT WT
22 138 mut G12V 12.9 mut
23 325 mut G12D 56.1 mut
24 140 WT a WT WT
25 7 mut G12C 61.2 mut
26 4 WT a WT WT
27 27 WT a WT WT
28 13 WT a WT WT
29 207 mut G12D 54.5 mut
30 10 failed WT G12V 1.5 WT b
31 54 WT a WT WT
32 120 mut G12V 29.2 mut
33 33 failed mut G12C 33.5 mut
34 N/A mut G12C 71.4 mut
35 N/A WT WT WT
36 N/A failed WT WT
37 67 WT a WT WT
38 137 mut G12C 76.7 mut
39 63 mut G12A 56 mut
40 13 WT a WT WT
41 113 WT a WT WT
Table 1 KRAS codon 12/13 status by HRM and pyrosequencing
in 61 CRC samples (Continued)
42 82 mut G12C 75.4 mut
43 39 WT WT WT
44 7 WT a G12S 2 WT b
45 23 WT a WT WT
46 24 faileda G13D 3.5 WT b
47 9 WT a WT WT
48 34 WT a G12S 2 WT b
49 25 WT a WT WT
50 17 WT WT WT
51 5 WT a WT WT
52 29 WT a WT WT
53 31 mut G12D 71.3 mut
54 68 WT WT WT
55 93 mut G12D 74.2 mut
56 221 WT WT WT
57 83 WT WT WT
58 N/A WT a G12V 1.2 WT b
59 35 mut G12D 83.3 mut
60 N/A WT WT WT
61 37 WT a WT WT
aSkewed HRM curve
bLOD/threshold for potential low level mutation (cf. Therascreen KRAS Pyro Kit
handbook version 1, July 2011): G12D 2.2 %/5.2 %, G12V 1.0 %/4.0 %, G12C
2.1 %/5.1 %, G12S 1.9 %/4.9 %, G13D 1.9 %/4.9 %
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the detection limit of the Nanodrop spectrophotometer
not necessarily prevented successful HRM analysis. In
contrast to HRM, the pyrosequencing assay had to be
repeated for only one sample (Table 1). Thus, the failure
rate of a first analysis run as a consequence of technical
and/or sample-issues was significantly higher for HRM
analysis than for pyrosequencing (p = 0.0042). Together,
pyrosequencing is technically more reliable than HRM
due to lower input requirements and a lower incidence
of invalid results.
Concordance of HRM and pyrosequencing results
In order to evaluate the diagnostic validity of HRM ana-
lysis as a basic test for KRAS mutation detection, we
compared the results from this assay to pyrosequencing
in the 57 samples that could be successfully analysed by
both methods. KRAS status was assigned concordantly
for 56 samples (98.2 %; kappa = 0.961), while the result
for one sample with a low mutant allele frequency of
13.4 % (#3, Table 1) was inconsistent between HRM and
pyrosequencing (Tables 1 and 2). Importantly, pyrose-
quencing indicated the presence of potential low level
mutations (mutant allele frequency < 4.0–5.2 %, cf.
Table 1) in four samples that were called WT by HRM.
Given that this output is generated due to low signal
strength for the potential mutation near the technical
detection limit of the pyrosequencing method we finally
classified these samples as WT. Conversely, all 19 sam-
ples that were clearly identified as mutant by HRM were
classified identically by pyrosequencing. Therefore, de-
fining pyrosequencing as the reference method, the spe-
cificity of HRM for detection of mutant KRAS alleles
Table 2 Comparison of HRM and pyrosequencing results in 61 CRC samples
Run 1 Run 2 Summary
Summary of Results
HRM n % n % n %
Number of samples 61 100.0 7 100.0 (11.5) 61 100.0
Analysis passed 50 82.0 7 100.0 57 93.4
WT (total) 32 64.0 6 85.7 38 66.7
WT (skewed HRM curve) 24 75.0 2 33.3 26 68.4
Mutant (total) 18 36.0 1 14.3 19 33.3
Mutant (skewed HRM curve) 0 0 0
Analysis failed 11 18.0 0
Pyrosequencing n % n % n %
Number of samples 61 100.0 1 100.0 (1.6) 61 100.0
Analysis passed 60 98.4 1 100.0 61 100.0
WT (total) 41 68.3 0 41 67.2
WT (call: WT) 35 58.3 35
WT (call: potential low level mutation) 6 10.0 0 6
Mutant 19 31.7 1 100.0 20 32.8
Analysis failed 1 1.6 0
Concordance of Results HRM Pyrosequencing
n % n %
Number of samples 57 100 57 100
WT (total) 38 66.7 37 64.9
WT (call: WT) 33 57.9
WT (call: potential low level mutation) 4 7.0
Mutant 19 33.3 20 35.1
Concordant 56 98.2
Discordant 1 1.8
Correctly classified WT 37 97.4
Incorrectly classified WT 1 2.6
Correctly classified mutant 19 100
Incorrectly classified mutant 0 0
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was 100 %. On the other hand, the specificity for the de-
tection of WT alleles was slightly reduced (97.4 %) due
to erroneous interpretation of the HRM curve for the
one sample mentioned (#3, Table 1) with a mutant allele
frequency only slightly above the sensitivity threshold of
the method. When we applied a different HRM assay for
the detection of NRAS codon 61 mutations on an inde-
pendent set of 19 CRC samples, we found a 100 %
concordance of results with reports from a reference la-
boratory (Additional file 1: Table S1). Of note, sensitivity
of the NRAS HRM assay was comparable to the KRAS
assay and allowed for reliable identification of mutations
at a mutant sample fraction of 20 % (Additional file 2:
Figure S1). Taken together, these findings indicate that
HRM represents a very reliable basic method for KRAS
mutation testing.
Two-step KRAS mutation testing in routine diagnostics
To evaluate the actual effectiveness of our two-step ana-
lysis platform (Fig. 3) in a routine diagnostic setting, we
reviewed effort and outcome of KRAS codon 12/13
mutation testing in 120 independent colorectal cancer
Fig. 3 Outline of the two-step procedure for KRAS codon 12/13 mutation analysis. Genomic DNA from microdissected colorectal cancer cells from
FFPE samples is subjected to HRM of a PCR amplicon spanning the mutation-bearing region of interest. For samples that are clearly identified as
KRAS mutant or, respectively, WT, the HRM result is incorporated in the final diagnostic report. Samples for which HRM analysis fails technically or
which yield ambiguous HRM curves are further evaluated by a second round of HRM and, if results are still invalid, to pyrosequencing. Note that
samples for which a WT result is obtained by the diagnostic procedure outlined here require further examination for additional KRAS and NRAS
mutations
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Table 3 Detailed results of KRAS codon 12/13 mutation testing
in 120 CRC samples
HRM Pyrosequencing













62 541 WT a WT WT
63 29 WT a WT WT
64 378 WT WT
65 342 WT a WT WT
66 176 failed WT a G12V 3.2 G12V 5.2 WT
67 139 mut mut
68 520 WT WT
69 42 WT WT
70 202 WT WT
71 157 mut mut
72 259 mut mut
73 145 WT WT
74 21 failed failed WT WT
75 22 failed WT WT
76 66 mut mut
77 55 mut mut
78 199 mut mut
79 197 WT WT
80 171 WT WT
81 55 failed G12V 41.1 mut
82 231 failed WT WT
83 250 failed WT WT
84 57 failed WT a WT
85 21 mut mut
86 248 WT WT
87 258 WT WT
88 83 failed failed failed N/A
89 38 failed WT WT
90 279 WT WT
91 122 failed WT WT





93 58 WT WT
94 129 WT WT
95 254 WT WT
96 373 WT WT
97 158 WT WT
98 96 mut mut
99 22 WT WT
100 30 mut mut
101 26 muta muta G13D 7.3 mut
Table 3 Detailed results of KRAS codon 12/13 mutation testing
in 120 CRC samples (Continued)
102 49 WT WT
103 47 WT WT
104 43 WT WT
105 54 WT WT
106 363 failed mut mut
107 521 failed WT WT
108 199 mut mut
109 260 WT WT
110 67 WT WT
111 103 WT WT
112 24 mut mut
113 150 WT WT
114 5 WT WT
115 25 WT WT
116 33 WT WT
117 26 mut mut
118 72 WT WT
119 16 failed G12V 12.8 mut
120 33 failed WT WT
121 48 WT WT
122 74 WT WT
123 474 mut mut
124 431 mut mut
125 66 mut mut
126 143 mut mut
127 49 failed WT WT
128 143 WT WT
129 122 mut mut
130 139 WT WT
131 21 failed WT WT
132 39 failed WT WT
133 128 failed G12D 26.7 mut
134 60 mut mut
135 330 failed mut mut
136 165 mut mut
137 213 mut mut
138 31 failed mut mut
139 156 mut mut
140 59 WT WT
141 68 WT WT
142 164 WT WT
143 238 mut mut
144 12 mut mut
145 33 failed WT WT
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samples that were examined consecutively in our labora-
tory according to this concept (Table 3). We found, that
KRAS status could be determined for 87.5 % of samples
by HRM and for 99.2 % of samples in total, when pyro-
sequencing was applied to samples that could not be
successfully analysed by HRM (Table 4). However, for
both HRM and pyrosequencing, the failure rate was
slightly higher than anticipated based on the observa-
tions from our initial 61 sample set (Tables 2 and 4).
Also of note, the number of samples that were subjected
to pyrosequencing in routine diagnostics exceeded the
previously estimated need of this analysis (19/120 =
15.5 % vs. 4/61 = 6.6 %) because 15 samples were directly
analysed by pyrosequencing after the first failed HRM run
in order to utilize otherwise wasted capacities. Yet, in
summary, these data strongly support the rationale of our
two-step approach to KRAS codon 12/13 mutation ana-
lysis, confirming the accuracy of our diagnostic platform.
Assay costs
In order to estimate the economic benefits of our two-
step approach to KRAS mutation testing, we compared
analysis costs in our routine setting to a pyrosequencing-
only platform. Based on current list prices for reagents
and consumables, we estimated the assay costs for HRM
analysis and pyrosequencing at approximately € 7.50 and
€ 100, respectively (Table 5). The costs for the essential
technical devices for both methods have not been
converted to per-sample costs because operation ex-
penses are highly dependent on sample throughput,
including not only the KRAS mutation assay but also
other applications. Moreover, investments for tech-
nical equipment are in the same range for pyrose-
quencing and HRM. Considering the failure rates of
each assay in our set of 120 routine samples (23.6 %
for HRM and 9.1 % for pyrosequencing), leading to
repeated testing of some samples, our two-step ap-
proach allows for net reduction of operational costs
of approximately 75 % compared to pyrosequencing
alone. Moreover, according to our experience, hands-
on time for processing the maximum number of sam-
ples for one HRM-run (14 + 4 controls) is only half of
the time required to prepare and perform a pyrose-
quencing run at full capacity (22 + 2 controls)
(Table 5). Therefore, our concept to maintain two se-
quential assays for KRAS codon 12/13 mutation test-
ing represents cost- and time-effective approach for
routine diagnostics.
Discussion
Here we present a two-step approach to KRAS codon
12/13 mutation testing for mCRC employing HRM ana-
lysis and pyrosequencing using the Therascreeen KRAS
Pyro Kit. Comparing the performance of the two
methods in a panel of 61 samples, we observed a 98.2 %
concordance of results with a 100 % specificity of HRM
for the detection of mutant alleles. Thus, HRM analysis
needs methodically independent confirmation of results
by pyrosequencing only in exceptional cases and there-
fore can serve as a filter assay to exclude clearly WT or
mutant samples from the more expensive and more
Table 3 Detailed results of KRAS codon 12/13 mutation testing
in 120 CRC samples (Continued)
146 81 WT WT
147 11 WT WT
148 13 mut mut
149 71 WT WT
150 11 mut mut
151 40 failed WT WT
152 50 WT WT
153 128 mut mut
154 146 WT WT
155 69 WT WT
156 182 WT WT
157 32 failed WT WT
158 142 WT WT
159 53 WT WT
160 91 failed WT WT
161 334 WT WT
162 86 failed WT WT
163 61 WT WT
164 64 WT WT
165 141 WT WT
166 271 WT WT
167 40 WT WT
168 34 failed WT WT
169 29 failed failed WT WT
170 354 WT WT
171 66 WT WT
172 43 failed WT WT
173 114 WT WT
174 268 WT WT
175 107 WT WT
176 170 mut mut
177 65 failed mut mut
178 31 failed mut mut
179 61 WT WT
180 659 mut mut
181 34 WT WT
aSkewed HRM curve
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laborious pyrosequencing analysis. Specifically, based on
our observations reported here, this approach can re-
duce throughput of the pyrosequencing assay by >85 %,
resulting in a >75 % cost reduction compared to using
pyrosequencing only. We emphasize, that our compari-
son of the two methods in the first place aimed on diag-
nostic accuracy for sequential application in order to
establish a reliable and economized platform for KRAS
mutation testing. Of note, we reached this goal in spite
we were able to detect mutant KRAS alleles only at a
frequency >12.5 % instead of 5 % as reported in the lit-
erature [20, 26].
With respect to technical performance, although
we successfully applied HRM to very low input sam-
ples, we state a clear advantage for the pyrosequenc-
ing assay due to lower input requirements and an
apparently relatively high susceptibility of HRM to
artifacts. More precisely, previous authors have
pointed out, that especially WT HRM curves show a
certain degree of variation resulting from poor quality
of FFPE-derived template DNA, differing salt- or inhibitor
concentrations or unspecific amplification [20, 27], that
may complicate correct determination of KRAS status.
Consistent with this notion, 6 of the 7 samples in our 61-
sample validation set that were subjected to a second
round of HRM analysis due to poor interpretability of first
round results were eventually called WT by this method.
Conversely, we did not obtain false positive results by
HRM, i.e., none of our samples that had been identified as
mutant by HRM was found to be WT according to pyro-
sequencing. Yet, we state that the mutation frequency of









14 samples + 4 controls 60
22 samples + 2 controls 120
Costs for the controls were estimated based on the maximum number of
samples that can be processed in one HRM- or pyrosequencing run,
respectively. Costs for HRM controls also include DNA isolation from KRAS WT
and mutant cell lines. Hands-on time is indicated for full capacity runs
Table 4 Operational analysis of two-step KRAS mutation testing of 120 CRC samples
Run 1 Run 2 Summary
HRM n % n % n %
Number of samples 120 100.0 20 100.0 (16.7) 120 100.0
Analysis passed 89 74.2 18 90.0 105 87.5
WT (total) 60 67.4 12 66.7 71 67.6
WT (skewed HRM curve) 3 5.0 2 16.7 4 5.6
Mutant (total) 29 32.6 6 33.3 34 32.4
Mutant (skewed HRM curve) 1 3.4 1 16.7 1 2.9
Analysis failed 31 25.8 2 10.0
Pyrosequencing n % n % n %
Number of samples 19 100.0 (15.8) 3 100.0 (2.5) 19 100.0
Analysis passed 18 94.7 2 66.7 18 94.7
WT 12 66.7 0 0.0 13 72.2
Potential low level mutation 2 11.1 1 50.0 0 0.0
Mutant 4 22.2 1 50.0 5 27.8
Analysis failed 1 5.3 1 33.3 1
Combined HRM + Pyrosequencing n %
Number of samples 120 100.0
Number of HRM runs 140 116.7
Number of pyrosequencing runs 22 18.3
Analysis passed 119 99.2
WT 81 68.1
Mutant 38 31.9
Analysis failed 1 0.8
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KRAS codon 12/13 observed in our study was slightly
lower than reported in the literature [9, 10], which may be
explained by our homogenous patient population from a
single center (Marburg, Germany).
Concerning diagnostic value of results from our se-
quential KRAS mutation analysis procedure, it is import-
ant to point out that pyrosequencing results include
information on the site, type and frequency of the
nucleotide exchange, while HRM only allows for cat-
egorical discrimination of WT and mutant tumors. Ac-
cording to current standards, such a dual output is
actually sufficient to establish the indication for anti-
EGFR treatment, although certain authors have sug-
gested that not all KRAS mutations are equal regarding
outcome in mCRC patients treated with cetuximab [3].
Consequently, as clinical routine testing at present in
principle does not require sequence-based analysis, the
more differentiated output of the pyrosequencing assay
does not warrant the higher costs for this analysis.
Therefore, the two-step procedure for KRAS mutation
testing presented here represents a reasonable diagnostic
approach not only from a technical-practical and eco-
nomical, but also from a clinical perspective. More spe-
cifically, using our diagnostic platform focused on KRAS
codon 12/13 mutation testing, even small diagnostic la-
boratories can provide accurate and clinically meaningful
results within a short processing time for the most rele-
vant genetic alteration that determines a treatment deci-
sion for mCRC patients. Consequently, only a small
fraction of patient samples has to be sent to an external
reference laboratory for further molecular studies in
accordance with the current EMA standards and recom-
mendations by the American Society of Clinical Oncol-
ogy, which state that Ras mutation testing prior to
initiation of treatment with cetuximab and panitumu-
mab has to include analysis of both KRAS and NRAS
exons 2, 3 and 4 (codons 12, 13, 59, 61, 117 and 146).
Also of note, besides KRAS and NRAS mutations, alter-
ations in several other genes such as BRAF and PIK3CA
have been proposed to predict outcome with EGFR anti-
body treatment [28–30]. Thus, identification of patients
eligible for cetuximab or panitumumab treatment in fact
requires either a broad panel of single mutation tests or
a multiplex approach. Optimized methods for DNA
melting analysis of short PCR amplicons have been
suggested to allow for comprehensive hot spot muta-
tion testing in a clinical setting as they require only
standard qPCR equipment. However, each assay re-
quires careful optimization, implying considerable ef-
forts for a diagnostic laboratory to set up all tests on
site [31]. Alternatively, next generation sequencing
(NGS) with a targeted resequencing approach appears
to be a suitable technology for extensive clinically
relevant mutation testing in the future, which has already
been evaluated for the molecular diagnostics of colorectal
cancer [32, 33]. Given the high frequency of KRAS codon
12/13 mutations compared to other KRAS- or NRAS mu-
tations and the fact that these mutations occur mutually
exclusive [10], it still seems reasonable, to filter the sam-
ples that actually need advanced testing method as pro-
posed here. Thus, a two-step approach including HRM
analysis of KRAS codon 12/13 mutations followed by next
generation targeted resequencing might be the most at-
tractive implementation for routine KRAS mutation diag-
nostics in the future.
Conclusion
We present a diagnostically reliable and cost-effective
two-step approach to KRAS codon 12/13 mutation testing
of CRC samples prior to initiation of treatment with anti-
EGFR antibodies. The platform appears to be especially
attractive for small to medium diagnostic laboratories that
don’t have the capacities to maintain an extensive
spectrum of rare mutation tests according to regulatory
standards for diagnostic laboratories [34] or to adopt
NGS-technology with its complex associated infrastruc-
ture including bioinformatics.
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